Trials / Completed
CompletedNCT00485576
Safety and Efficacy Study of Eculizumab in Patients With Mild Allergic Asthma
A Randomized, Double Blind, Placebo-Controlled, Crossover Study to Evaluate the Safety and Efficacy of Eculizumab in Subjects With Mild Allergic Asthma.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- Alexion Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is to designed to test the role of complement in the late asthmatic response to allergen challenge in mild asthma, as an indicator of the possible role of complement in the broader asthmatic population.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | eculizumab | eculizumab 600 mg or matching placebo iv infusion. |
Timeline
- Start date
- 2007-09-01
- Primary completion
- 2008-09-01
- Completion
- 2008-11-01
- First posted
- 2007-06-13
- Last updated
- 2009-01-15
Locations
2 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT00485576. Inclusion in this directory is not an endorsement.